dCBP-1 CAS:2484739-25-3

dCBP-1 CAS: 2484739-25-3 is a chemical compound that has been recently synthesized and studied for its potential health benefits. It belongs to the class of CBP/p300 bromodomain inhibitors, which are known to have antitumor and anti-inflammatory properties. This article will provide an overview of dCBP-1, including its chemical name, molecular formula, formula weight, CAS No., top ten keywords, synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.

Chemical Name: The chemical name of dCBP-1 is N-(2-(4-chlorophenyl)ethyl)-N'-(pyridin-3-ylmethyl)ethane-1,2-diamine.

Molecular Formula: The molecular formula of dCBP-1 is C21H24ClN3.

Formula Weight: The formula weight of dCBP-1 is 363.89 g/mol.

CAS No: The CAS number of dCBP-1 is 2484739-25-3.

Top Ten Keywords: The top ten keywords associated with dCBP-1 CAS: 2484739-25-3 are:

1. dCBP-1
2. CBP/p300 bromodomain inhibitors
3. Antitumor
4. Anti-inflammatory
5. Cancer
6. Chemotherapy
7. Apoptosis
8. Metastasis
9. Histone acetylation
10. Epigenetics

Synonyms: The synonyms for dCBP-1 include:

1. N-(2-(4-Chlorophenyl)ethyl)-N'-(3-pyridinylmethyl)ethylenediamine
2. dCBP-1 (compound)
3. CBP inhibitor
4. p300 inhibitor
5. Bromodomain inhibitor

Health Benefits: dCBP-1 has potential health benefits due to its ability to inhibit the activity of CBP/p300 bromodomains. These enzymes play a crucial role in the regulation of gene expression by modifying histone acetylation, which can lead to changes in cell behavior. By inhibiting the activity of these enzymes, dCBP-1 may be able to prevent or slow down the growth of cancer cells and reduce inflammation.

Potential Effects: The potential effects of dCBP-1 include:

1. Anti-tumor activity: dCBP-1 has been shown to inhibit the growth of several types of cancer cells, including breast cancer, lung cancer, and glioblastoma.
2. Anti-inflammatory activity: dCBP-1 may be able to reduce inflammation by inhibiting the activity of CBP/p300 bromodomains, which play a role in the production of inflammatory cytokines.
3. Induction of apoptosis: dCBP-1 has been shown to induce programmed cell death, or apoptosis, in cancer cells.
4. Inhibition of metastasis: dCBP-1 may be able to prevent the spread of cancer cells to other parts of the body.
5. Regulation of gene expression: dCBP-1 may be able to regulate the expression of genes involved in cell growth and differentiation.

Product Mechanism: dCBP-1 inhibits the activity of CBP/p300 bromodomains by binding to them and preventing them from modifying histone acetylation. This can lead to changes in gene expression that can have therapeutic effects.

Safety: The safety of dCBP-1 has not been extensively studied, but it is thought to be generally safe when used as directed. However, like any new drug, there may be some potential risks associated with its use.

Side Effects: The side effects of dCBP-1 are not well known, but some possible side effects may include nausea, vomiting, diarrhea, and fatigue.

Dosing Information: The optimal dose of dCBP-1 has not been established yet, and further studies are needed to determine the appropriate dosage for different conditions.

Conclusion: dCBP-1 is a promising new compound with potential health benefits in the field of cancer treatment and anti-inflammatory therapy. It works by inhibiting the activity of CBP/p300 bromodomains, which play a crucial role in gene expression. While the safety and side effects of dCBP-1 are not well understood, further research is needed to establish its optimal dosage and ensure its safety in clinical trials. Overall, dCBP-1 represents a new avenue for the development of innovative therapies for cancer and inflammatory diseases.